Literature DB >> 11137760

Proteasomal function is impaired in substantia nigra in Parkinson's disease.

K S McNaught1, P Jenner.   

Abstract

The accumulation of alpha-synuclein, ubiquitin and other proteins in Lewy bodies in degenerating dopaminergic neurones in substantia nigra in idiopathic Parkinson's disease (PD) suggest that inhibition of normal/abnormal protein degradation may contribute to neuronal death. We now show for the first time that the chymotrypsin- (39%), trypsin- (42%) and postacidic-like (33%) hydrolysing activities of 20/26S proteasome are impaired in substantia nigra in PD. Proteasome inhibition does not appear to result from drug treatment since high concentrations of L-3,4-dihydroxyphenylalanine had no effect on enzymatic activity in vitro. These observations provide the first direct evidence that inhibition of the ubiquitin-proteasome pathway leading to altered protein handling and Lewy body formation may be responsible for degeneration of the nigrostriatal pathway in idiopathic PD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137760     DOI: 10.1016/s0304-3940(00)01701-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  160 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 2.  Neuroprotection in Parkinson's disease: an elusive goal.

Authors:  William C Koller; Maria G Cersosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

3.  Mild heat stress stimulates 20S proteasome and its 11S activator in human fibroblasts undergoing aging in vitro.

Authors:  Rasmus Beedholm; Brian F C Clark; Suresh I S Rattan
Journal:  Cell Stress Chaperones       Date:  2004-03       Impact factor: 3.667

Review 4.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

5.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

6.  Studying protein degradation pathways in vivo using a cranial window-based approach.

Authors:  Vivek K Unni; Darius Ebrahimi-Fakhari; Charles R Vanderburg; Pamela J McLean; Bradley T Hyman
Journal:  Methods       Date:  2010-12-25       Impact factor: 3.608

7.  α-Synuclein fate is determined by USP9X-regulated monoubiquitination.

Authors:  Ruth Rott; Raymonde Szargel; Joseph Haskin; Rina Bandopadhyay; Andrew J Lees; Vered Shani; Simone Engelender
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

8.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

9.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

10.  Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.

Authors:  Arthur P Chou; Nigel Maidment; Rebecka Klintenberg; John E Casida; Sharon Li; Arthur G Fitzmaurice; Pierre-Olivier Fernagut; Farzad Mortazavi; Marie-Francoise Chesselet; Jeff M Bronstein
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.